DOI QR코드

DOI QR Code

Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics

  • Tabriz, Hedieh Moradi (Department of Pathology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Olfati, Golrokh (Department of Pathology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Ahmadi, Seyed Ali (Department of Pathology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Yusefnia, Sudabeh (Department of Pathology, Sina Hospital, Tehran University of Medical Sciences)
  • Published : 2013.08.30

Abstract

Background: Transitional cell carcinoma (TCC) is the most predominant type of urinary bladder tumor. As cyclooxygenase (COX)-2 is recently introduced as an attractive target molecule in bladder TCC, we evaluated the immunohistochemical expression of this marker and its association with several clinicopathological characteristics. Materials and Methods: This cross-sectional study was performed in the Pathology department of Sina Hospital in Tehran, Iran during 2006-2011. Ninety-two paraffin embedded blocks were selected from patients with urinary bladder TCC who underwent cystectomy or transurethral resection (TUR). Then, we assessed COX-2 expression by immunohistochemical staining using antibody against COX-2. Staining in more than 5% of tumor cells was considered as positive expression. Results: COX-2 was expressed in 50 % of our patients. This marker was markedly expressed in high grade bladder TCC (62.1%) versus other grades and there was statistically a significant difference in COX-2 expression between various grades (p=0.008). In addition, patients' age, lymphatic and perineurial invasion were associated with the expression of COX-2 (p=0.001, 0.015 and 0.039, respectively). However, other parameters such as stage, tumor size, venous invasion and lymph node metastasis did not show any significant relationship with this marker (all, p>0.05). Conclusions: COX-2 was expressed in urinary bladder TCC especially in high grade forms, advocating its probable role in the differentiation of this tumor. Accordingly, COX-2 could be a valuable biological target molecule in the evaluation and treatment of patients with bladder TCC.

Keywords

Cyclooxygenase-2;urinary bladder;transitional cell carcinoma;immunohistochemistry

References

  1. Bulbul MA, Husseini N, Houjaji A (2005). Superficial bladder cancer epidemiology, diagnosis and management. J Med Liban, 53, 107-13.
  2. Dhawan D, Craig BA, Cheng L, et al (2010). Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther, 9, 1371-7. https://doi.org/10.1158/1535-7163.MCT-10-0049
  3. Edge SB, Byrd DR, Compton CC, et al (2010). AJCC cancer staging manual, 7nd ed., Springer, New York, 497-50.
  4. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998). The world Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol, 22, 1435-48. https://doi.org/10.1097/00000478-199812000-00001
  5. Eschwege P, Ferlicot S, Droupy S, et al (2003). A histopathologic investigation of PGE (2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol, 44, 435-41. https://doi.org/10.1016/S0302-2838(03)00313-0
  6. Gangwar R, Mandhani A, Mittal RD (2011). Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery, 149, 126-34. https://doi.org/10.1016/j.surg.2010.04.004
  7. Gurocak S, Sozen S, Erdem O, et al (2006). Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. Urol Int, 76, 51-6. https://doi.org/10.1159/000089735
  8. Jang TJ, Lee KS (2009).The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma. Korean J Pathol, 43, 206-11. https://doi.org/10.4132/KoreanJPathol.2009.43.3.206
  9. Kim SI, Kwon SM, Kim YS, Hong SJ (2002). Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 60, 816-21. https://doi.org/10.1016/S0090-4295(02)01909-X
  10. Koki AT, Masferrer JL (2002). Celecoxib: a specific cox-2 inhibitor with anticancer properties. Cancer Control, 9, 28-35.
  11. Komhoff M, Guan Y, Shappell HW, et al (2000). Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157, 29-35. https://doi.org/10.1016/S0002-9440(10)64513-0
  12. Margulis V, Shariat SF, Ashfaq R, et al (2007). Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of the bladder. J Urol, 177, 1163-8. https://doi.org/10.1016/j.juro.2006.10.033
  13. Matsuzawa I, Kondo Y, Kimura G, et al (2002). Cyclooxygenase-2 expression and relationship to malignant potential in human bladder cancer. J Health Sci, 48, 42-7. https://doi.org/10.1248/jhs.48.42
  14. Meric JB, Rottey S, Olaussen K, et al (2006). Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol, 59, 51-64. https://doi.org/10.1016/j.critrevonc.2006.01.003
  15. Mohamed SF, Mohamed HAD (2012). The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma. Egyp J Pathol, 32, 150-4 https://doi.org/10.1097/01.XEJ.0000417560.37231.66
  16. Naruse K, Yamada Y, Nakamura K, et al (2010). Potential of molecular targeted therapy of HER-2 and COX-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep, 23, 1577-83.
  17. Okamoto A, Shirakawa T, Bito T, et al (2008). Etodolac ,a selective cyclooxygenase-2 inhibitor , induces upregulation of E-Cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71, 156-60. https://doi.org/10.1016/j.urology.2007.09.061
  18. Parkin DM (2008). The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 218, 12-20.
  19. Pruthi RS, Derksen E, Gaston K, Wallen EM (2004). Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology, 64, 637-42. https://doi.org/10.1016/j.urology.2004.04.047
  20. Raspollini MR, Taddei GL (2007). Cyclooxygenase -2: a novel target in human solid tumors. Curr Oncol Rep, 9, 96-101. https://doi.org/10.1007/s11912-007-0004-5
  21. Ristimaki A, Nieminen O, Saukkonen K, et al (2001). Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol, 158, 849-53. https://doi.org/10.1016/S0002-9440(10)64033-3
  22. Sadjadi A, Nouraie M, Mohagheghi M, et al (2005). Cancer Occurrence in Iran in 2002, an International Perspective. Asian Pac J Cancer Prev, 6, 359-63.
  23. Shariat SF, Kim JH, Ayala GE, et al (2003a). Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol, 169, 938-42. https://doi.org/10.1097/01.ju.0000043638.89552.ed
  24. Shariat SF, Matsumoto K, Kim J, et al (2003b).Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol, 170, 985-9. https://doi.org/10.1097/01.ju.0000080401.85145.ee
  25. Shirahama T (2000). Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res, 6, 2424-30.
  26. Shirahama T, Arima J, Akiba S, Sakakura C (2001). Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92, 188-93. https://doi.org/10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W
  27. Song T, Zhang X, Wang C, et al (2011). Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev, 12, 929-33.
  28. Wadhwa P, Goswami AK, Joshi K, Sharma SK (2005).Cyclooxygenase -2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol, 37, 47-53. https://doi.org/10.1007/s11255-004-4699-z
  29. Wulfing C, Eltze E, Von Struensee D, et al (2004). Cyclooxygenase-2 expression in bladder cancer : correlation with poor outcome after chemotherapy. Eur Urol, 45, 46-52. https://doi.org/10.1016/j.eururo.2003.08.007
  30. Yamada Y, Nakamura K, Inoue Y, et al (2008). Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder. Mol Med Report, 1, 791-5.
  31. Yulizar DR, Hardjowijoto S, Djatisoesanto W, Soemarno T (2008). Difference in cyclooxygenase-2 (COX-2) expression between low and high grade papillary carcinoma in human bladder cancer. Folia Medica Indonesiana, 44 ,71-5.
  32. Zhu Z, Shen Z, Xu C (2012). Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm, 528690, 11.

Cited by

  1. Group IIA in Esophageal Squamous Cell Carcinoma and Association with Cyclooxygenase-2 Expression vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9417
  2. Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10813